Altrinsic Global Advisors’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Altrinsic Global Advisors’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-162,000	Closed	-$2.76M	–	93
2020 Q4	$2.76M	Buy	162,000 +72,000	+80%	+$902K	0.09%	51
2020 Q3	$423K	Hold	90,000	–	–	0.02%	82
2020 Q2	$549K	Hold	90,000	–	–	0.02%	78
2020 Q1	$204K	Hold	90,000	–	–	0.01%	79
2019 Q4	$413K	Hold	90,000	–	–	0.02%	72
2019 Q3	$349K	Hold	90,000	–	–	0.02%	76
2019 Q2	$543K	Hold	90,000	–	–	0.03%	78
2019 Q1	$1.21M	Hold	90,000	–	–	0.06%	73
2018 Q4	$837K	Hold	90,000	–	–	0.04%	71
2018 Q3	$1.25M	Hold	90,000	–	–	0.06%	69
2018 Q2	$1.42M	Hold	90,000	–	–	0.06%	68
2018 Q1	$1.55M	Buy	90,000 +10,000	+13%	+$195K	0.06%	66
2017 Q4	$1.75M	Buy	+80,000	New	+$2.57M	0.07%	68

Other funds holding FPRX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Altrinsic Global Advisors's FPRX Position: Q1 2021 in Review

Altrinsic Global Advisors sold out of Five Prime Therapeutics, Inc. (FPRX) in Q1 2021, closing a stake of 162,000 shares — an estimated $2.76M sold.

Altrinsic Global Advisors first reported a position in FPRX in Q4 2017 and held it in 13 quarters. The position peaked at $2.76M in Q4 2020. 147 funds tracked by Wall St. Rank hold FPRX as of Q1 2021.

Altrinsic Global Advisors reported no remaining Five Prime Therapeutics, Inc. position as of Q1 2021 after selling out during the quarter.
Altrinsic Global Advisors sold 162,000 Five Prime Therapeutics, Inc. shares in Q1 2021, an estimated $2.76M.
Altrinsic Global Advisors first reported a position in Five Prime Therapeutics, Inc. in Q4 2017 and held it in 13 quarters.
Altrinsic Global Advisors's Five Prime Therapeutics, Inc. position peaked at $2.76M in Q4 2020.
147 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q1 2021.

Based on Altrinsic Global Advisors's 13F filing for Q1 2021, filed 14 May 2021.